₩14750.00
₩0.00 (0.00%)
End-of-day quote: 05/24/2024
KOSE:A003220
Daewon Pharmaceutical Annual Report
| Year | Year | 2023 | 2022 | 2021 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rev. | Revenue |
|
₩526.95B | ₩478.88B | ₩354.18B | ₩317.83B | ₩286.65B | ₩265.46B | ₩240.72B | ₩216.19B | ₩181.98B | ₩158.88B | ₩138.17B | ₩138.87B | |
| GM % | Gross Margin % |
|
48.42% | 49.25% | 49.28% | 56.13% | 57.13% | 56.65% | 56.47% | 53.52% | 54.36% | 52.73% | 51.66% | 54.81% | |
| OM | Operating Margin |
|
6.12% | 8.96% | 5.45% | 11.00% | 10.67% | 9.49% | 12.11% | 10.55% | 9.78% | 9.78% | 9.75% | 9.64% | |
| EPS | Earnings Per Share |
|
₩0.00 | ₩1.11k | ₩1.48k | ₩339.00 | ₩1.30k | ₩1.13k | ₩522.94 | ₩952.91 | ₩838.12 | ₩758.94 | ₩596.12 | ₩486.12 | ₩478.70 |
| Div. | Dividends |
|
₩350.00 | ₩200.00 | ₩200.00 | ₩240.41 | ₩233.40 | ₩226.61 | ₩166.01 | ₩161.18 | ₩117.36 | ₩0.00 | ₩0.00 | ₩0.00 | |
| PR % | Payout Ratio % |
|
31.53% | 13.52% | 59.00% | 18.45% | 20.59% | 43.33% | 17.42% | 19.23% | 15.46% | 0 | 0 | 0 | |
| Sha. | Shares |
|
21.2m | 20.97m | 21.22m | 20.94m | 20.33m | 19.95m | 20.34m | 20.5m | 20.11m | 20.11m | 19.2m | 19.2m | |
| OCF | Operating Cash Flow |
|
₩51.73B | ₩33.33B | ₩22.41B | ₩30.97B | ₩40.03B | ₩4.27B | ₩20.79B | ₩25.82B | ₩17.45B | ₩12.32B | ₩13.83B | ₩17.93B | |
| FCF | Free Cash Flow |
|
₩24.00B | ₩25.32B | ₩18.31B | ₩7.80B | ₩-784.95M | ₩5.80B | ₩10.92B | ₩6.01B | ₩4.40B | ₩2.47B | ₩10.52B | ₩7.78B | |
| FCFS | Free Cash Flow Per Share |
|
₩1.48k | ₩943.39 | ₩504.57 | ₩-271.26 | ₩-121.74 | ₩-659.90 | ₩26.60 | ₩123.67 | ₩86.82 | ₩116.21 | ₩521.18 | ₩381.99 |
